These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 9387313)

  • 1. [In vivo antitumor effects of polyethylene glycol--modified recombinant human interleukin-2 on mouse uterine cervical carcinoma].
    Wang L; Wu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 1996 Jul; 18(4):253-5. PubMed ID: 9387313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vivo antitumor activities of polyethylene glycol modified recombinant interleukin 2 (PEG-rIL-2) against murine hepatoma].
    Feng XS
    Zhonghua Zhong Liu Za Zhi; 1993 Jul; 15(4):256-8. PubMed ID: 8174461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyethylene-glycol-modified interleukin-2 is superior to interleukin-2 in locoregional immunotherapy of established guinea-pig tumors.
    Mattijssen V; Balemans LT; Steerenberg PA; De Mulder PH
    Int J Cancer; 1992 Jul; 51(5):812-7. PubMed ID: 1612787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine studies using polyethylene glycol-modified recombinant human interleukin 2 (PEG-IL-2): antitumor effects of PEG-IL2 alone and in combination with adoptive cellular transfer.
    Yang JC; Schwarz SL; Perry-Lalley DM; Rosenberg SA
    Lymphokine Cytokine Res; 1991 Dec; 10(6):475-80. PubMed ID: 1804310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reevaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2.
    Bernsen MR; Dullens HF; Den Otter W; Heintz PM
    J Interferon Cytokine Res; 1995 Jul; 15(7):641-5. PubMed ID: 7553236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol.
    Katre NV
    J Immunol; 1990 Jan; 144(1):209-13. PubMed ID: 2295792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The anti-tumor efficacy of human recombinant interleukin-2 (rIL-2) in vivo].
    Wang C; Chai L; Zhu G
    Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):27-9. PubMed ID: 7656782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
    George S; Hutson TE; Mekhail T; Wood L; Finke J; Elson P; Dreicer R; Bukowski RM
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):347-54. PubMed ID: 17909807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.
    Ootsu K; Gotoh K; Houkan T
    Cancer Immunol Immunother; 1989; 30(2):71-80. PubMed ID: 2598180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumor models.
    Zimmerman RJ; Aukerman SL; Katre NV; Winkelhake JL; Young JD
    Cancer Res; 1989 Dec; 49(23):6521-8. PubMed ID: 2819708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An anti-IL-2 antibody increases serum half-life and improves anti-tumor efficacy of human recombinant interleukin-2.
    Courtney LP; Phelps JL; Karavodin LM
    Immunopharmacology; 1994; 28(3):223-32. PubMed ID: 7852053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M
    J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marked reduction of subcutaneous tumor growth by intraperitoneal administration of recombinant human interleukin 2 with a cell accumulator, proteose-peptone, in mice.
    Tanida S; Uchida H; Taniguchi K; Nomoto K
    Cancer Res; 1989 Jan; 49(2):284-8. PubMed ID: 2783379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2: use in solid tumors.
    Bukowski RM; McLain D; Olencki T; Budd GT; Murthy SA
    Stem Cells; 1993 Jan; 11(1):26-32. PubMed ID: 8457777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effects of 5'-deoxy-5-fluorouridine in combination with recombinant human interleukin 2 on murine colon carcinoma 26.
    Midoro K; Gotoh K; Houkan T; Yukishige K; Fujiwara K; Ootsu K
    Jpn J Cancer Res; 1997 Mar; 88(3):306-15. PubMed ID: 9140116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined effect of intraperitoneally administered OK-432 and recombinant interleukin (rIL-2) against mouse tumors].
    Fujioka T; Shiraishi M; Tanji S; Koike H; Kumagai K; Kubo T; Ohhori T
    Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):948-56. PubMed ID: 2789265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The success of locoregional, low-dose recombinant interleukin-2 therapy in tumor-bearing mice is dependent on the time of rIL-2 administration.
    Everse LA; Bernsen MR; Dullens HF; Den Otter W
    J Exp Ther Oncol; 1996 Jul; 1(4):231-6. PubMed ID: 9414409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.